![Christopher Rex](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Rex
Geen lopende functies
Profiel
Christopher Rex is the founder of Afraxis, Inc., a company founded in 2007.
He held the title of Chief Scientific Officer from 2013 to 2021.
Dr. Rex also worked as a Program Director at T123 LLC from 2018 to 2021.
He obtained a doctorate degree from the University of California, Irvine in 2008 and an undergraduate degree from the University of California, Santa Barbara in 2002.
Eerdere bekende functies van Christopher Rex
| Bedrijven | Functie | Einde |
|---|---|---|
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of fragile X syndrome and autism | Oprichter | 01-09-2021 |
T123 LLC
 T123 LLC Investment ManagersFinance T123 invests in companies located in the United States. The firm targets companies operating in the field of drug development industry. It provides financing for early stage capital requirements. | Directeur/Bestuurslid | 01-04-2021 |
Opleiding van Christopher Rex
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
90
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of fragile X syndrome and autism | Health Technology |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
T123 LLC
T123 LLC Investment ManagersFinance T123 invests in companies located in the United States. The firm targets companies operating in the field of drug development industry. It provides financing for early stage capital requirements. | Finance |
Kies MarketScreener 
